Literature DB >> 21718992

Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial.

Juan A Garcia-Velasco1, Alfonso Bermejo, Francisco Ruiz, Javier Martinez-Salazar, Antonio Requena, Antonio Pellicer.   

Abstract

OBJECTIVE: To compare cycle outcomes after scheduling with the standard long protocol versus the use of oral contraceptive pills (OCPs) in patients undergoing GnRH antagonist cycles.
DESIGN: Prospective, randomized, controlled trial.
SETTING: University-affiliated private assisted reproduction center. PATIENT(S): Regularly cycling women aged ≤38 years with fewer than three previous IVF attempts were enrolled. Previous low responses to controlled ovarian hyperstimulation, ovarian surgery, or polycystic ovary were exclusion criteria. INTERVENTION(S): One hundred fifteen patients received OCP (0.030 ethinyl E(2)/0.15 desogestrel) for 12-16 days, and controlled ovarian hyperstimulation was started on day 5 after OCP treatment; similarly, 113 patients received the long protocol from day 20-22 of the previous cycle. MAIN OUTCOME MEASURE(S): The primary outcome was ongoing pregnancy rate; secondary outcome variables were clinical pregnancy rate, live birth rate, implantation rate, and miscarriage rate. RESULT(S): Patients receiving the GnRH antagonist treatment showed a lower peak serum E(2) (1,334 vs. 1,823 pg/mL) but similar peak serum PE (0.58 vs. 0.65 ng/mL), lower duration of the stimulation (10.3 vs. 11.4 days) with similar FSH consumption (1,613 vs. 1,807 IU), and ovarian response (10.2 vs. 11.7 oocytes). No differences were observed in the fertilization rates (68.1% vs. 64.8%), total number of embryos obtained (5.9 vs. 6.2), mean number of embryos transferred (1.8 vs. 1.8), implantation rate (36% vs. 39%), miscarriage rate (8.9% vs. 17%), ongoing pregnancy rate (47.8% vs. 53.9%), or live birth rate (44.3% vs. 47%). CONCLUSION(S): Comparable outcomes can be obtained using OCP containing 0.030 ethinyl E(2)/0.15 desogestrel to schedule patients undergoing the antagonist protocol.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718992     DOI: 10.1016/j.fertnstert.2011.06.022

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  13 in total

1.  Study of two strategies to induce follicular wave emergence for assisted reproductive treatments (ART)-a preliminary trial.

Authors:  Paulo H M Bianchi; Lais M Viera; Gabriela R F C A Gouveia; André M Rocha; Pietro S Baruselli; Edmund C Baracat; Paulo C Serafini
Journal:  J Assist Reprod Genet       Date:  2015-02-21       Impact factor: 3.412

2.  Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial ISRCTN69937179.

Authors:  Mostafa I Abuzeid; Mohamed Mitwally; Yasmine M Abuzeid; Hammad A Bokhari; Mohammad Ashraf; Michael P Diamond
Journal:  J Assist Reprod Genet       Date:  2012-09-08       Impact factor: 3.412

3.  Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial.

Authors:  Erik E Hauzman; Azucena Zapata; Alfonso Bermejo; Carlos Iglesias; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Reprod Biol Endocrinol       Date:  2013-09-28       Impact factor: 5.211

4.  Serum progesterone elevation adversely affects cumulative live birth rate in different ovarian responders during in vitro fertilization and embryo transfer: a large retrospective study.

Authors:  Zhiqin Bu; Feifei Zhao; Keyan Wang; Yihong Guo; Yingchun Su; Jun Zhai; Yingpu Sun
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

Review 5.  Scheduling cycles with gonadotropin-releasing hormone antagonist protocol in in vitro fertilization: Is there a scope in batch in vitro fertilization?

Authors:  Rohit Gutgutia; Sameer Rao; Juan Garcia-Velasco; Susmita Basu
Journal:  J Hum Reprod Sci       Date:  2014 Oct-Dec

6.  Morphokinetic behavior of euploid and aneuploid embryos analyzed by time-lapse in embryoscope.

Authors:  Deven V Patel; Preeti B Shah; Aditi P Kotdawala; Javier Herrero; Irene Rubio; Manish R Banker
Journal:  J Hum Reprod Sci       Date:  2016 Apr-Jun

7.  Pretreatment of normal responders in fresh in vitro fertilization cycles: A comparison of transdermal estradiol and oral contraceptive pills.

Authors:  Nigel Pereira; Allison C Petrini; Zhen N Zhou; Jovana P Lekovich; Isaac Kligman; Zev Rosenwaks
Journal:  Clin Exp Reprod Med       Date:  2016-12-26

8.  Progesterone elevation on the day of human chorionic gonadotropin administration adversely affects the outcome of IVF with transferred embryos at different developmental stages.

Authors:  Yan Huang; En-Yin Wang; Qing-Yun Du; Yu-Jing Xiong; Xiao-Yi Guo; Yi-Ping Yu; Ying-Pu Sun
Journal:  Reprod Biol Endocrinol       Date:  2015-08-04       Impact factor: 5.211

9.  Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs.

Authors:  Haiyan Lin; Yu Li; Lin Li; Wenjun Wang; Dongzi Yang; Qingxue Zhang
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

10.  Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT.

Authors:  Ensieh Shahrokh Tehrani Nejad; Fatemeh Bakhtiari Ghaleh; Bita Eslami; Fedyeh Haghollahi; Maryam Bagheri; Masoumeh Masoumi
Journal:  Int J Reprod Biomed       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.